200 related articles for article (PubMed ID: 7503756)
1. Properties of the reversible, K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. II. Pharmacological properties.
Parsons ME; Rushant B; Rasmussen TC; Leach C; Ife RJ; Postius S; Pope AJ
Biochem Pharmacol; 1995 Nov; 50(10):1551-6. PubMed ID: 7503756
[TBL] [Abstract][Full Text] [Related]
2. Properties of the reversible K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. I. In vitro activity.
Pope AJ; Boehm MK; Leach C; Ife RJ; Keeling D; Parsons ME
Biochem Pharmacol; 1995 Nov; 50(10):1543-9. PubMed ID: 7503755
[TBL] [Abstract][Full Text] [Related]
3. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
4. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands.
Kirchhoff P; Andersson K; Socrates T; Sidani S; Kosiek O; Geibel JP
Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G838-43. PubMed ID: 16798725
[TBL] [Abstract][Full Text] [Related]
6. SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H+ + K+)-ATPase.
Keeling DJ; Malcolm RC; Laing SM; Ife RJ; Leach CA
Biochem Pharmacol; 1991 Jun; 42(1):123-30. PubMed ID: 1648919
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of gastric acid secretion by omeprazole in the dog and rat.
Larsson H; Carlsson E; Junggren U; Olbe L; Sjöstrand SE; Skånberg I; Sundell G
Gastroenterology; 1983 Oct; 85(4):900-7. PubMed ID: 6884713
[TBL] [Abstract][Full Text] [Related]
8. Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats.
Kinoshita M; Saito N; Tamaki H
Eur J Pharmacol; 1997 Mar; 321(3):325-32. PubMed ID: 9085044
[TBL] [Abstract][Full Text] [Related]
9. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
[TBL] [Abstract][Full Text] [Related]
10. Antisecretory and antiulcer effects of YM020, a new H+,K(+)-ATPase inhibitor, in rats and dogs.
Yuki H; Kamato T; Nishida A; Ohta M; Shikama H; Yanagisawa I; Miyata K
Jpn J Pharmacol; 1995 Jan; 67(1):59-67. PubMed ID: 7745846
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
[TBL] [Abstract][Full Text] [Related]
12. Time course of inhibition of gastric acid secretion by omeprazole and ranitidine in gastric fistula rats.
Seensalu R; Girma K; Romell B; Nilsson G
Eur J Pharmacol; 1990 May; 180(1):145-52. PubMed ID: 2364999
[TBL] [Abstract][Full Text] [Related]
13. Soraprazan: setting new standards in inhibition of gastric acid secretion.
Simon WA; Herrmann M; Klein T; Shin JM; Huber R; Senn-Bilfinger J; Postius S
J Pharmacol Exp Ther; 2007 Jun; 321(3):866-74. PubMed ID: 17369284
[TBL] [Abstract][Full Text] [Related]
14. Nicotinamide derivatives as a new class of gastric (H+/K+)-ATPase inhibitors. III. Synthesis and gastric antisecretory activity of 2-[(2- and 4-aminobenzyl, and alpha-methylbenzyl)sulfinyl]-N-(4-pyridinyl) -3-pyridinecarboxamides.
Terauchi H; Tanitame A; Tada K; Nakamura K; Seto Y; Nishikawa Y
Chem Pharm Bull (Tokyo); 1997 Jul; 45(7):1177-82. PubMed ID: 9246752
[TBL] [Abstract][Full Text] [Related]
15. Reversible inhibitors of the gastric (H+/K+)-ATPase. 2. 1-Arylpyrrolo[3,2-c]quinolines: effect of the 4-substituent.
Leach CA; Brown TH; Ife RJ; Keeling DJ; Laing SM; Parsons ME; Price CA; Wiggall KJ
J Med Chem; 1992 May; 35(10):1845-52. PubMed ID: 1316968
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole and cimetidine versus pentagastrin in canine ex vivo gastric chamber.
Larsen KR; Ives MM; Jensen NF; Carlsson E; Larsson H
Am J Physiol; 1989 Feb; 256(2 Pt 1):G390-5. PubMed ID: 2919682
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats.
Kim KB; Chang MS; Chung YK; Sohn SK; Kim SG; Choi WS
J Pharm Pharmacol; 1998 May; 50(5):521-9. PubMed ID: 9643446
[TBL] [Abstract][Full Text] [Related]
18. Reversible and potent uncoupling of hog gastric (H(+)+K(+))-ATPase by prodigiosins.
Matsuya H; Okamoto M; Ochi T; Nishikawa A; Shimizu S; Kataoka T; Nagai K; Wasserman HH; Ohkuma S
Biochem Pharmacol; 2000 Dec; 60(12):1855-63. PubMed ID: 11108801
[TBL] [Abstract][Full Text] [Related]
19. Cyclic AMP in gastric juice does not reflect histamine H2 receptor activity in Heidenhain pouch dog.
Kumagai J; Oka H; Kaneko E; Honda N
Gastroenterol Jpn; 1986 Oct; 21(5):465-70. PubMed ID: 3023163
[TBL] [Abstract][Full Text] [Related]
20. AHR-9294: a novel inhibitor of H,K-ATPase antagonizes gastric HCl secretion in vivo.
Reenstra WW; Pinkus LM; Bailey J; Smith WL; Droppleman D; Sancilio LF; Forte JG
J Pharmacol Exp Ther; 1992 May; 261(2):737-45. PubMed ID: 1315865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
